Fermenta Biotech Lists on NSE, Enhancing Market Accessibility
Fermenta Biotech's equity shares are now listed on the NSE effective August 4, 2026. This dual listing on both NSE and BSE aims to increase investor accessibility and market visibility. The company celebrates this milestone in its 75-year journey.
The dual listing is expected to enhance market accessibility and visibility, which can positively influence investor participation and potentially stock liquidity.
The listing on a major stock exchange like NSE is a positive development for the company, indicating growth and increased investor interest.
Fermenta Biotech Limited announced the successful listing of its equity shares on the National Stock Exchange of India Limited (NSE) effective August 4, 2026. The company's 2,94,30,987 equity shares, with a face value of ₹5 each, will now trade on both NSE under the symbol FERMENTA and on the BSE under Scrip Code 506414.
This dual listing marks a significant milestone in Fermenta's 75-year history, having been founded in 1951 and listed on the BSE since 1977. The company, a leading manufacturer of Vitamin D3 API and other nutritional ingredients, aims to increase accessibility for a wider community of investors and enhance market visibility.
Prashant Nagre, Managing Director of Fermenta, stated that the NSE listing strengthens the company's capital market presence and reaffirms its commitment to transparency and governance. He expressed appreciation to all stakeholders for their continued confidence.
What to do with a filing like this
Fermenta Biotech Limited filed this with the NSE as a statutory disclosure, categorised under other company updates. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fermenta Biotech Limited. Read the original for the full detail.